<SEC-DOCUMENT>0001104659-20-046360.txt : 20200414
<SEC-HEADER>0001104659-20-046360.hdr.sgml : 20200414
<ACCEPTANCE-DATETIME>20200414160648
ACCESSION NUMBER:		0001104659-20-046360
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20200414
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200414
DATE AS OF CHANGE:		20200414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		20791435

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2015825d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>April 14, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; width: 32%; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding: 0; width: 2%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 32%; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="padding: 0; width: 2%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 32%; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of <BR>
incorporation or organization)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR&nbsp;230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule&nbsp;14a-12 under the Exchange Act (17 CFR&nbsp;240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR&nbsp;240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR&nbsp;240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading symbol(s)</FONT></TD>
    <TD STYLE="width: 33%; border: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR>
    <TD STYLE="border-left: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.001 par value per share</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; padding: 1.5pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
<TR>
    <TD STYLE="border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD STYLE="border-left: black 1pt solid; padding: 1.5pt; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect; 240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3.03 Material Modifications of
Rights of Security Holders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth in Item 5.03 is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.03 Amendments to Articles of
Incorporation or Bylaws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Amendment to Amended and Restated Certificate of Incorporation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 14, 2020,
Cyclacel Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) filed a certificate of amendment to its amended and restated certificate
of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company&rsquo;s
shares of common stock. The reverse stock split, which was unanimously approved by the Company&rsquo;s board of directors, was
approved by the Company&rsquo;s stockholders at a special meeting of stockholders held on October 28, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
reverse stock split, every twenty (20) shares of the Company&rsquo;s pre-reverse split common stock will be combined and reclassified
into one (1) share of common stock. Proportionate voting rights and other rights of common stock holders will not be affected by
the reverse stock split. Stockholders who would otherwise hold a fractional share of common stock will receive payment in cash
in lieu of any such resulting fractional shares of common stock as the post-reverse split amounts of common stock will be rounded
down to the nearest full share. Such cash payment in lieu of a fractional share of common stock will be calculated by multiplying
such fractional interest in one share of common stock by the closing trading price of the Company&rsquo;s common stock on the trading
day immediately preceding the effective date of the reverse stock split, and rounded to the nearest cent. No fractional shares
will be issued in connection with the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reverse stock split
is intended to increase the per share trading price of the Company&rsquo;s common stock to satisfy the $1.00 minimum bid price
requirement for continued listing on The Nasdaq Stock Market LLC. The reverse stock split will be effective at 5:00 p.m., Eastern
Time, on April 14, 2020, and the Company&rsquo;s common stock will trade on The Nasdaq Stock Market LLC on a post-reverse split
basis at the open of business on April 15, 2020. The Company&rsquo;s post-reverse split common stock has a new CUSIP number (CUSIP
No. 23254L603), but the par value and other terms of the common stock are not affected by the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
transfer agent, American Stock Transfer &amp; Trust Company, LLC, is acting as exchange agent for the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9;On April 14, 2020, the Company issued
a press release with respect to the reverse stock split, which is being filed as Exhibit 99.1 to this Current Report on Form 8-K.
A copy of the certificate of amendment to the amended and restated certificate of incorporation is being filed as Exhibit 3.1 to
this Current Report on Form 8-K and is incorporated herein by reference.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exhibits. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; white-space: nowrap; width: 10%; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
    <TD STYLE="padding: 0 0 1pt; width: 2%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; white-space: nowrap; width: 88%; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0"><A HREF="tm2015825d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; vertical-align: top; text-indent: 0"><A HREF="tm2015825d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc., filed with the Secretary of State of the State of Delaware on April 14, 2020</FONT></A></TD></TR>
<TR>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0"><A HREF="tm2015825d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; vertical-align: top; text-indent: 0"><A HREF="tm2015825d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release Issued by Cyclacel Pharmaceuticals, Inc. on April 14, 2020</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>Cyclacel Pharmaceuticals, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: April 14, 2020</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 25%"><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Executive Vice President &mdash; Finance, Chief Financial Officer and Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 59.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2015825d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT<BR>
TO THE<BR>
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<BR>
OF<BR>
CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;242 of<BR>
the General Corporation Law of the<BR>
State of Delaware</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cyclacel Pharmaceuticals, Inc., a corporation
organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &ldquo;Corporation&rdquo;),
does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FIRST:</B>&nbsp;&nbsp;&nbsp; The Board
of Directors of the Corporation duly adopted resolutions approving the following amendment to the Corporation&rsquo;s Amended and
Restated Certificate of Incorporation (the &ldquo;Certificate of Incorporation&rdquo;), declaring said amendment to be advisable
and providing for the consideration of such amendment at a special meeting of stockholders of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECOND:</B>&nbsp;&nbsp;&nbsp; On October&nbsp;28,
2019, the special meeting of stockholders of the Corporation was duly called and held, upon notice in accordance with Section&nbsp;222
of the General Corporation Law of the State of Delaware, at which meeting the necessary number of shares required by statute were
voted in favor of the amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIRD:</B>&nbsp;&nbsp;&nbsp; Said amendment
was duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FOURTH:</B>&nbsp;&nbsp;&nbsp; Section
(C) of Article&nbsp;FOURTH of the Certificate of Incorporation is hereby amended in its entirety to state the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Effective as of&thinsp; 5:00 p.m.,
New York City time, on April 14, 2020 (the &ldquo;<U>Effective Time</U>&rdquo;), each twenty (20) shares of Common Stock issued
and outstanding or held as treasury shares immediately prior to the Effective Time (the &ldquo;<U>Old Common Stock</U>&rdquo;)
shall automatically and without any action on the part of the holder thereof be reclassified, combined and converted into one (1)&nbsp;share
of Common Stock (the &ldquo;<U>New Common Stock</U>&rdquo;) (such reclassification, combination and conversion, the &ldquo;<U>Reverse
Stock Split</U>&rdquo;). Notwithstanding the immediately preceding sentence, no fractional shares of New Common Stock shall be
issued to holders of record of Old Common Stock as of the Effective Time. In lieu thereof, each holder of record of Old Common
Stock as of the Effective Time that would otherwise be entitled to receive a fractional share of New Common Stock as a result of
the Reverse Stock Split shall be entitled to receive, upon surrender of certificates representing such Old Common Stock, a cash
payment in an amount equal to the fraction to which the stockholder would otherwise be entitled multiplied by the then-prevailing
price as reported by The NASDAQ Stock Market (or if such price is not available, then such other price as determined by the Board
of Directors). The ownership of a fractional share of New Common Stock shall not give the holder any voting, dividend or other
rights, except the right to receive the cash payment described in the immediately preceding sentence. Whether or not the Reverse
Stock Split would result in fractional shares for a holder of record of Old Common Stock as of the Effective Time shall be determined
on the basis of the total number of shares of Old Common Stock held by such holder of record as of the Effective Time. Each stock
certificate that, immediately prior to the Effective Time, represented shares of Old Common Stock shall, from and after the Effective
Time, automatically and without the necessity of presenting the same for exchange, represent the number of whole shares of New
Common Stock into which the shares of Old Common Stock represented by such certificate shall have been reclassified, combined and
converted in the Reverse Stock Split (as well as the right to receive cash in lieu of fractional shares as described above). The
New Common Stock issued in the Reverse Stock Split shall have the rights, preferences and privileges as the Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FIFTH:</B>&nbsp;&nbsp;&nbsp; The foregoing
amendment to the Certificate of Incorporation shall be effective as of 12:01&nbsp;am Eastern Daylight Time on April 14, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, Cyclacel Pharmaceuticals,
Inc. has caused this Certificate of Amendment to the Certificate of Incorporation to be signed by the undersigned, thereunto duly
appointed, this April 14, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; width: 50%; border-bottom: white 1pt solid; text-indent: 0"><FONT STYLE="font-size: 10pt">&#8203;</FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; width: 5%; border-bottom: white 1pt solid; text-indent: 0"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; width: 45%; border-bottom: black 1pt solid; text-indent: 0"><FONT STYLE="font-size: 10pt"><I>/s/ Spiro Rombotis </I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">&#8203;</FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">&#8203;</FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">Spiro Rombotis </FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">&#8203;</FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">&#8203;</FONT></TD>
    <TD STYLE="padding: 0; white-space: nowrap; text-indent: 0"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2015825d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 50%; font-size: 10pt; text-indent: 0"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 65px; width: 174px"></TD>
    <TD STYLE="vertical-align: middle; text-align: right; padding: 0; width: 50%; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 26px; width: 572px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Announces REVERSE STOCK SPLIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Berkeley Heights,
NJ, April 14, 2020</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;),
a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that effective at 5:00
p.m., Eastern Time, on April 14, 2020 (the &ldquo;Effective Time&rdquo;), the Company will effect a one-for-twenty reverse stock
split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company&rsquo;s Board of
Directors, was approved by its stockholders at a Special Meeting of Stockholders held on October 28, 2019. The Company&rsquo;s
common stock will open for trading on The NASDAQ Capital Market on April 15, 2020 on a post-split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the reverse stock split, every twenty shares
of the Company's common stock issued and outstanding at the Effective Time will be consolidated into one issued and outstanding
share. No fractional shares of common stock will be issued as a result of the reverse stock split; stockholders will be paid cash
in lieu of any such fractional shares. Proportional adjustments will be made to Cyclacel&rsquo;s outstanding warrants and stock
options. The Company&rsquo;s authorized shares and the nominal par value per share of $0.001 will remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, upon the effectiveness of the reverse stock split,
the conversion of Cyclacel&rsquo;s outstanding 6% convertible exchangeable preferred stock and series A convertible preferred stock
will be adjusted proportionally and automatically in accordance with the terms of the Company&rsquo;s Certificate of the Powers,
Designations, Preferences and Rights of the 6% Convertible Exchangeable Preferred Stock and Certificate of Designation of Preferences,
Rights and Limitations of the Series A Convertible Preferred Stock, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reverse stock split is intended to increase the per share
trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ
Capital Market. Trading of the Company&rsquo;s common stock on The NASDAQ Capital Market will continue, on a split-adjusted basis,
with the opening of the markets on Wednesday, April 15, 2020, under the existing trading symbol &ldquo;CYCC&rdquo; and under a
new CUSIP number 23254L603. The reverse stock split reduces the number of shares of the Company&rsquo;s common stock outstanding
from approximately 17.2 million pre-reverse split shares to approximately 860,000 post-reverse split shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information for Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has retained its transfer
agent, American Stock Transfer &amp; Trust Company, LLC (&quot;AST&quot;), to act as its exchange agent for the reverse stock
split. AST will provide stockholders of record as of the Effective Time a letter of transmittal providing instructions for the
exchange of their stock certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically
adjusted to reflect the reverse stock split, subject to such brokers' particular processes, and will not be required to take any
action in connection with the reverse stock split. For more information regarding the reverse stock split, please refer to the
Company&rsquo;s definitive proxy statement for its most recently held annual meeting of stockholders which can be accessed through
Cyclacel&rsquo;s website at http://www.cyclacel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Wingdings; color: Gray">&thorn;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Gray">200 Connell Drive, Suite 1500, Berkeley Heights,
New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Wingdings; color: Gray">&uml;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Gray">1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44
1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Gray">&#9;<U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel Pharmaceuticals&nbsp;is
a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation
and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors
and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is
evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An IST is evaluating
an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating
CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients.&nbsp;Cyclacel's&nbsp;strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a pipeline of novel drug candidates. Please visit www.cyclacel.com
for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
 &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations: Russo Partners LLC, Jan Medina<FONT STYLE="color: #2E2E2E; background-color: white">,
(646) 942-5632,&nbsp;</FONT>Jan.Medina@russopartnersllc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&copy;
<FONT STYLE="background-color: white">Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The&nbsp;</FONT>Cyclacel<FONT STYLE="background-color: white">&nbsp;logo
and&nbsp;</FONT>Cyclacel<FONT STYLE="background-color: white"><SUP>&reg;</SUP>&nbsp;are trademarks of&nbsp;</FONT>Cyclacel Pharmaceuticals,
Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! *X# 2(  A$! Q$!_\0
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M.R"TC> NXD8DCY<?+P#G'!KKK_2=)L=3M+JVA-MJ$K,L,=OE$N&"%MCX! &
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>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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MME_S\)1_:ME_S\)1_:ME_P _"4?VK9?\_"4?VK9?\_"4?VK9?\_"4?VK9?\
M/PE']JV7_/PE']JV7_/PE']JV7_/PE']JV7_ #\)1_:ME_S\)1_:ME_S\)1_
M:ME_S\)1_:ME_P _"4?VK9?\_"4?VK9?\_"4?VK9?\_"4?VK9?\ /PE']JV7
M_/PE']JV7_/PE']JV7_/PE']JV7_ #\)1_:ME_S\)1_:ME_S\)1_:ME_S\)1
M_:ME_P _"4?VK9?\_"4?VK9?\_"4?VK9?\_"4?VK9?\ /PE']JV7_/PE']JV
M7_/PE']JV7_/PE']JV7_ #\)1_:ME_S\)1_:ME_S\)1_:ME_S\)1_:ME_P _
M*5;!! (Z&EHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
3HHHHHHHHHHHHHHHHHHHHHK__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
